Suven Pharmaceuticals Limited

NSE SUVENPHAR.NS

Suven Pharmaceuticals Limited Operating Income Margin for the year ending March 31, 2024: 43.83%

Suven Pharmaceuticals Limited Operating Income Margin is 43.83% for the year ending March 31, 2024, a 13.22% change year over year. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.

Suven Pharmaceuticals Limited Operating Income Margin for the year ending March 31, 2023 was 38.71%, a -7.82% change year over year.
Suven Pharmaceuticals Limited Operating Income Margin for the year ending March 31, 2022 was 41.99%, a 0.39% change year over year.
Suven Pharmaceuticals Limited Operating Income Margin for the year ending March 31, 2021 was 41.83%, a -5.82% change year over year.
Suven Pharmaceuticals Limited Operating Income Margin for the year ending March 31, 2020 was 44.41%, a -58.35% change year over year.

Key data

Date	Operating Income Margin	EBT Margin	Net Income Margin	EBITDA Margin

NSE: SUVENPHAR.NS

Suven Pharmaceuticals Limited

CEO	Dr. Sudhir Kumar Singh Ph.D.
IPO Date	March 9, 2020
Location	India
Headquarters	# 8-2-334, SDE Serene Chambers
Employees	1,193
Sector	Health Care
Industries Pharmaceuticals Biotechnology Chemicals & Advanced Materials

Description

Suven Pharmaceuticals Limited operates as a bio-pharmaceutical company in India, the United States, Europe, and internationally. It develops, manufactures, and sells new chemical entity-based intermediates, active pharmaceutical ingredients, specialty chemicals, and formulated drugs under contract research and manufacturing services for pharmaceutical, biotechnology, and chemical companies. The company was incorporated in 2018 and is headquartered in Hyderabad, India. Suven Pharmaceuticals Limited is a subsidiary of Jasti Property and Equity Holdings Private Limited.

Key trends

Past 5 years